Vaccination studies against diabetes are going in a positive direction!

Diabetes company Diamyd today announced that a clinically relevant and positive course of action has been demonstrated in terms of both the ability to produce own insulin, such as long-term blood sugar and insulin dose. No serious adverse reactions have been reported. This after all Diagnode-1 diabetes patients have been followed for 6 months. - The results seen in Diagnode-1 are pleasing now that all twelve patients have been followed for 6 months. That is why with enthusiasm we begin Diagnode-2, where we now screened our first patient. The own insulin production that remains in newly diagnosed type 1 diabetes patients is important to preserve, as even a lesser one simplifies the life of diabetes, decreases the number of hypoglycemias and leads to fewer long-term complications, "said Johnny Ludvigsson, professor at Linköping University and sponsor of the study. The report from the Diagnode-1 open-label trial, where the diabetes vaccine Diamyd is given directly in the lymphatic gland, now results are presented for all twelve patients followed for 6 months. No serious adverse events have been reported in the study, and positive effects can be seen in the course of the disease. At 6 months, their own ability to form insulin is virtually unchanged. On average, insulin production decreased by 1.7%, against expected 15%, while on average, patients have lower, -22% long-term blood sugar and use less insulin than at study start. Previously reported preliminary 15-month results for six participants show that their own insulin-producing ability decreased only by 10.8%, against expected 35%, and that long-term blood sugar and insulin dose decreased by 31% and 39%, respectively. The treatment also provides a desired immunological response. "Diagnostics 2, which we have now begun, will be very exciting and with participating clinics from Sweden, the Czech Republic and Spain, we will work together for effective patient recruitment," says Ulf Hannelius, CEO of Diamyd Medical.

Find the original article on: https://www.lifesciencesweden.se/article/view/572748/positivt_for_diabetesvaccin?ref=newsletter&utm_medium=email&utm_source=newsletter&utm_campaign=daily